CD274 and neoplasm: Nivolumab vs. standard therapy: in PD-L1+ patients, median OS: 8.7 vs. 4.6 months, HR: 0.55; in PD-L1− patients, median OS: 5.7 vs. 5.8 months, HR: 0.89; PD-L1+ (cutoff: ≥1% tumor cells, membranous expression, Dako 28-8) prevalence: 57.3%